||Novel Drugs and Treatment Strategies
Oral Abstract Session : Track A
||Session Room 7
||24.07.2012, 16:30 - 18:00
Daniel Kuritzkes, United States
Mirko Paiardini, United States
D. Kuritzkes, United States
|Pre-clinical evaluation of HIV replication inhibitors that target the HIV-integrase-LEDGF/p75 interaction|
F. Christ1, C. Pickford2, J. Demeulemeester1, S. Shaw2, B.A. Desimmie1, C. Smith-Burchnell2, S. Butler2, M. Westby2, Z. Debyser1
1KULeuven, Laboratory for Molecular Virology and Gene Therapy, Leuven, Belgium, 2Pfizer Inc, Sandwich, United Kingdom
F. Christ, Belgium
|Towards HIV eradication: excision of HIV-1 proviral DNA by Tre-recombinase in HIV-positive humanized mice|
H. Hofmann-Sieber1, I. Hauber1, J. Chemnitz1, A. Grundhoff1, J. Chusainow2, A. Schambach3, C. Baum3, P. Ziegler4, M. Manz5, F. Buchholz2, J. Hauber1
1Heinrich Pette Institute - Leibniz Institute for Experimental Virology, Hamburg, Germany, 2University of Technology Dresden, University Hospital and Medical Faculty Carl Gustav Carus, Department of Medical Systems Biology, Dresden, Germany, 3Hannover Medical School, Institute of Experimental Hematology, Hannover, Germany, 4Institute for Research in Biomedicine, Bellinzona, Switzerland, 5University Hospital Zurich, Zurich, Switzerland
H. Hofmann-Sieber, Germany
|In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells|
S. Kitchen, B. Levin, G. Bristol, V. Rezek, S. Kim, C. Aguilera-Sandoval, A. Balamurugan, O. Yang, J. Zack
David Geffen School of Medicine at UCLA, UCLA AIDS Institute, Los Angeles, United States
S. Kitchen, United States
|Oral serum-derived bovine immunoglobulin (SBI) administration leads to duodenal gastrointestinal-associated lymphoid tissue (GALT) CD4+ T-lymphocyte increases and improved small intestinal absorption function in an 8-week pilot study in patient|
D.M. Asmuth1, Z.-M. Ma2,3, A. Albanese4, S. Devaraj5, E. Hodzic2, J.-C. Garcia1, T.H. Knight1, N.M. Flynn1, S. Mann1,4, T. Yotter1, E. Tsuchida6, C.J. Miller2,3
1University of California Davis Medical Center, Sacramento, United States, 2University of California at Davis, Davis, United States, 3Center for Comparative Medicine, Davis, United States, 4Mather Veterans's Administration Hospital, Mather, United States, 5University of Texas Children's Hospital, Houston, United States, 6CARES Clinic, Sacramento, United States
D. Asmuth, United States
|Improved intestinal immunity and cytotoxic potential of T cells in interleukin (IL)-21 treated SIV-infected rhesus macaques|
S. Pallikkuth1, L. Micci2, Z. Ende2, R. Iriele2, B. Cervasi2, J. Else2, G. Silvestri2, F. Villinger2, S. Pahwa1, M. Paiardini2
1University of Miami Miller School of Medicine, Miami, United States, 2Emory University, Yerkes National Primate Research Center, Atlanta, United States
M. Paiardini, United States
Track A report by Irene Onyango
The search for novel HIV drugs and treatment strategies that can be used for prophylactic or therapeutic purposes in humans is ongoing. Ledgins are a novel class of inhibitors targeting HIV integrase, hence capable of blocking HIV replication, that could be used in combined HIV therapy.
Viral DNA integration into the host genome is a critical step in viral replication; even if anti-integrase drugs now exist, no therapetics have been able to reverse integration so far. The Max Plank Institute has developed Tre-recombinase that effectively excises HIV-1 proviral DNA from infected human cell cultures. These data suggest that Tre-recombinase may become a novel drug for antiretroviral therapy.
HIV specific CTL responses are critical in controlling viral replication, hence there is a need to enhance these responses to suppress and clear the virus. The positive preliminary results of a cell based therapeutic strategy that enhances CTL to eradicate the virus suggests that stem cell based gene therapy is a realistic approach.
Compromised mucosal integrity is involved in chronic immune activation, and HIV enteropathy persists despite ART. SBI has been shown to improve GI function and GALT CD4+ T cells. Th17 have been shown to be critical for mucosal immune function. The potential of IL22, which regulated IL17, should be explored as a potential immune modulator.